Claims
- 1. A taxane derivative having the formula whereinX1 is OX6, —SX7, or —NX8X9; X2 is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl; X3 and X4 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl; X5 is —COOX10; X6 is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxy protecting group, or a functional group which increases the water solubility of the taxane derivative; X7 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or sulfhydryl protecting group; X8 is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterosubstituted alkyl, alkenyl, alkynyl, aryl or heteroaryl; X9 is an amino protecting group; X10 is t-butyl; R1 is hydrogen, hydroxy, protected hydroxy, or together with R14 forms a carbonate; R2 is hydrogen, hydroxy, —OCOR31 or together with R2a forms an oxo; R2a is hydrogen or taken together with R2 forms an oxo or; R4 is hydrogen, together with R4a forms an oxo, oxirane or methylene, or together with R5a and the carbon atoms to which they are attached form an oxetane ring; R4a is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cyano, hydroxy, —OCOR30, or together with R4 forms an oxo, oxirane or methylene; R5 is hydrogen or together with R5a forms an oxo, R5a is hydrogen, hydroxy, protected hydroxy, acyloxy, together with R5 forms an oxo, or together with R4 and the carbon atoms to which they are attached form an oxetane ring; R5 is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl, hydroxy, protected hydroxy or together with R6a forms an oxo; R6a is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl, hydroxy, protected hydroxy or together with R6 forms an oxo; R7 is hydrogen or together with R7a forms an oxo, R7a is hydrogen, halogen, protected hydroxy, —OR28, or together with R7 forms an oxo; R9 is hydrogen or together with R9a forms an oxo, R9a is hydrogen, hydroxy, protected hydroxy, acyloxy, or together with R9 forms an oxo; R10 is hydrogen or together with R10a forms an oxo, R10a is hydrogen, —OCOR29, hydroxy, or protected hydroxy, or together with R10 forms an oxo; R14 is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl, hydroxy, protected hydroxy or together with R1 forms a carbonate; R14a is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl; R28 is hydrogen, acyl, hydroxy protecting group or a functional group which increases the solubility of the taxane derivative; R29, R30, and R31 are independently hydrogen, alkyl, alkenyl, alkynyl, monocyclic aryl or monocyclic heteroaryl, provided, however, at least one of R1-R31 has a value such that the structure of the taxane is different from that of docetaxel.
- 2. The taxane of claim 1 wherein X4 is hydrogen and X3 is isopropyl, cyclopropryl, n-butyl, t-butyl, amyl, cyclobutyl, cyclohexyl, furyl, thienyl or pryidyl.
- 3. The taxane of claim 1 wherein X4 is hydrogen, and X3 is isopropyl, cyclopropyl, n-butyl, t-butyl, amyl, cyclobutyl, cyclohexyl, furyl, thienyl, pyridyl or the substituted analogs thereof.
- 4. The taxane of claim 1 wherein X4 is hydrogen, and X3 is phenyl, isopropyl, cyclopropyl, n-butyl, t-butyl, amyl, cyclobutyl, cyclohexyl, furyl, pyridyl, thienyl or the substituted analogs thereof.
- 5. The taxane of claim 1 whereinX1 is —OX6, —SX7, or —NX8X9 and X6 is other than hydrogen or hydroxy protecting group; X2 is other than hydrogen; at least one of X3 and X4 is other than hydrogen and phenyl; R1 is hydroxy or together with R14 forms a carbonate; R2 is other than benzoyloxy; R4 and R5a and the carbon atoms to which they are attached do not form an oxetane ring; R4a is other than acetoxy; R6 and R6a are other than hydrogen; R7a is other than hydroxy; R9 and R9a together do not form an oxo; R10a is other than hydroxy; or R14 and R14a are other than hydrogen.
- 6. The taxane derivative of claim 1 wherein R2a is hydrogen and R2 is hydroxy or —OCOR31 wherein R31 is hydrogen, alkyl or selected from the group comprising and Z is alkyl, hydroxy, alkoxy, halogen, or trifluoromethyl.
- 7. The taxane derivative of claim 1 wherein R4 together with R5a and the carbons to which form an oxetane ring, R2a is hydrogen and R2 is hydroxy or —OCOR31 wherein R31 is hydrogen, alkyl or selected from the group comprising and Z is alkyl, hydroxy, alkoxy, halogen, or trifluoromethyl.
- 8. The taxane derivative of claim 1 wherein R7 is hydrogen and R7a is hydrogen or acetoxy.
- 9. The taxane derivative of claim 1 wherein R9 is hydrogen and R9a is hydrogen, hydroxy or acetoxy.
- 10. The taxane derivative of claim 1 wherein R10 is hydrogen or together with R10a forms an oxo and R10a is hydrogen, together with R10a forms an oxo or is other than hydroxy and acetoxy.
- 11. A pharmaceutical composition which contains the taxane derivative of claim 1 and one or more pharmacologically acceptable, inert or physiologically active diluents or adjuvants.
REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. Ser. No. 09/425,794, filed Oct. 22, 1999, now abandoned, which is a continuation application of U.S. Ser. No. 08/991,963, filed Dec. 17, 1997, now U.S. Pat. No. 6,018,073, which is a divisional/continuation application of U.S. Ser. No. 08/461,103, filed Jun. 5,1995, now U.S. Pat. No. 5,739,362, which is a file wrapper continuation application of U.S. Ser. No. 08/094,717 filed Jul. 20, 1993, now abandoned which is a continuation-in-part of application of U.S. Ser. No. 08/034,247, filed Mar. 22, 1993, now U.S. Pat. No. 5,430,160, which is a continuation-in-part application of U.S. Ser. No. 07/949,107, filed Sep. 22, 1992, now abandoned, which is a continuation-in-part application of U.S. Ser. No. 07/863,849, filed Apr. 6, 1992, now abandoned, which is a continuation-in-part application of U.S. Ser. No. 07/862,955, filed Apr. 3, 1992, now abandoned, which is a continuation-in-part of U.S. Ser. No. 07/763,805, filed Sep. 23, 1991, now abandoned. Said Ser. No. 08/094,717 is also a continuation-in-part application of U.S. Ser. No. 08/034,852, filed Mar. 22, 1993, now abandoned, which is a continuation-in-part of U.S. Ser. No. 07/975,723, filed Nov. 13, 1992, now U.S. Pat. No. 5,283,253, which is a continuation-in-part of U.S. Ser. No. 07/949,107, filed Sep. 22, 1992, now abandoned, which is a continuation-in-part application of U.S. Ser. No. 07/863,849, filed Apr. 6, 1992, now abandoned, which is a continuation-in-part application of U.S. Ser. No. 07/862,955, filed Apr. 3, 1992, now abandoned, which is a continuation-in-part of U.S. Ser. No. 07/763,805, filed Sep. 23, 1991, now abandoned. Said Ser. No. 08/094,717 is also a continuation-in-part application of U.S. Ser. No. 07/863,198, filed Apr. 3, 1992, now U.S. Pat. No. 5,243,045, which is a continuation-in-part of U.S. Ser. No. 07/763,805, filed Sep. 23, 1991, now abandoned.
Government Interests
This invention was made with Government support under NIH Grant #CA 42031 and NIH Grant #CA 55131 awarded by the National Institutes of Health. The Government has certain rights in the invention.
US Referenced Citations (43)
Foreign Referenced Citations (29)
Number |
Date |
Country |
9190838 |
Jun 1992 |
AU |
9223280 |
Jan 1993 |
AU |
9223880 |
Feb 1993 |
AU |
9335048 |
Aug 1993 |
AU |
9335050 |
Aug 1993 |
AU |
9337563 |
Sep 1993 |
AU |
9341556 |
Jan 1994 |
AU |
9351148 |
Apr 1994 |
AU |
9351151 |
Apr 1994 |
AU |
9351152 |
Apr 1994 |
AU |
9351153 |
Apr 1994 |
AU |
9453395 |
Apr 1994 |
AU |
9454257 |
May 1994 |
AU |
9455659 |
Jun 1994 |
AU |
9461446 |
Sep 1994 |
AU |
9463971 |
Sep 1994 |
AU |
0247378 |
Dec 1987 |
EP |
0253738 |
Jan 1988 |
EP |
0253739 |
Jan 1988 |
EP |
0336840 |
Oct 1989 |
EP |
0336841 |
Oct 1989 |
EP |
0400971 |
Dec 1990 |
EP |
0428376 |
May 1991 |
EP |
0534707 |
Mar 1993 |
EP |
0534708 |
Mar 1993 |
EP |
0534709 |
Mar 1993 |
EP |
WO 9209589 |
Jun 1992 |
WO |
WO 9302065 |
Feb 1993 |
WO |
919224 |
Nov 1990 |
ZA |
Non-Patent Literature Citations (12)
Entry |
Borman “New Family of Taxol, Taxotere Analogs Developed” Chem. & Engineering News, Science/Technology (Apr. 12, 1993) pp. 26-27. |
Denis et al. “A Highly Efficient Practical Approach to Natural Taxol” Journal of American Chemical Society, vol. 110, No. 17 (1988) pp. 5917-5919. |
Farina et al. “The Chemistry of Taxanes: Unexpected Rearrangement of Baccatin III During Chemoselective Debenzoylation with Bu3SnOMe/LiCl” Tetrahedron Letters, vol. 33, No. 28 (1992) pp. 3979-3982. |
Georg et al. “Novel Biologically Active TAxol Analogues: Baccatin III 13-(N-(p-Chlorobenzoyl)-(2′R,2′S)-3′-phenylisoserinate) and Baccatin III 13-(N-Benzoyl-(2′R,3′S)-3′-(p-chlorophenyl)isoserinate)” Bioorganic & Medicinal Chemistry Letters, vol. 2, No. 4 (1992) pp. 295-298. |
Holton et al. “A Synthesis of Taxusin”, Journal of American Chemical Society, vol. 110 (1988) pp. 6558-6560. |
Holton “Synthesis of the Taxane Ring System” Journal of American Chemical Society, vol. 106 (1984) pp. 5731-5732. |
Kingston et al. “Progress In the Chemistry of Organic Natural Products” Springer-Verlag, New York, NY (1993) pp. 1-206. |
Mukerjee et al. “β-Lactams: Retrospect and Prospect” Tetrahedron, vol. 34, No. 52 (1978) pp. 1731-1767. |
Ojima et al. “New and Efficient Approaches to the Semisynthesis of Taxol and its C-13 Side-Chain Analogs by Means of β-Lactam Synthon Method” Tetrahedron, vol. 48, No. 34 (1992) pp. 6985-7012. |
Samaranayake et al. “Modified Taxols. 5.1 Reaction of Taxol with Electrophilic Reagents and Preparation of a Rearranged Taxol Derivative with Tubulin Assembly Activity” Journal of Organic Chemistry, vol. 56, No. 7 (1991) pp. 5114-5119. |
Senilh et al. “Chime Organique Biologique-Hemisynthese de nouveaux analogue du taxol. Etude de leur interaction avec la tubuline” C.R. Acad. Sci. Paris, Serie II, t. 299, No. 15 (1984) pp. 1039-1043. |
Wani et al. “Plant Antitumor Agents. VI. The Isolation and Structure of Taxol, A Novel Antileukemic and Antitumor Agent from Taxus brevifolia” Journal of American Chemical Society, vol. 93, No. 9 (May 5, 1971) pp. 2325-2327. |
Continuations (4)
|
Number |
Date |
Country |
Parent |
09/425794 |
Oct 1999 |
US |
Child |
10/245167 |
|
US |
Parent |
08/991963 |
Dec 1997 |
US |
Child |
09/425794 |
|
US |
Parent |
08/461103 |
|
US |
Child |
08/461103 |
|
US |
Parent |
08/094717 |
Jul 1993 |
US |
Child |
08/461103 |
|
US |
Continuation in Parts (13)
|
Number |
Date |
Country |
Parent |
08/034247 |
Mar 1993 |
US |
Child |
08/094717 |
|
US |
Parent |
07/949107 |
Sep 1992 |
US |
Child |
08/034247 |
|
US |
Parent |
07/863849 |
Apr 1992 |
US |
Child |
07/949107 |
|
US |
Parent |
07/862955 |
Apr 1992 |
US |
Child |
07/863849 |
|
US |
Parent |
07/763805 |
Sep 1991 |
US |
Child |
07/862955 |
|
US |
Parent |
08/034852 |
Mar 1993 |
US |
Child |
08/094717 |
|
US |
Parent |
07/975723 |
Nov 1992 |
US |
Child |
08/034852 |
|
US |
Parent |
07/949107 |
|
US |
Child |
07/975723 |
|
US |
Parent |
07/863849 |
|
US |
Child |
07/949107 |
|
US |
Parent |
07/862955 |
|
US |
Child |
07/863849 |
|
US |
Parent |
07/763805 |
|
US |
Child |
07/862955 |
|
US |
Parent |
07/863198 |
Apr 1992 |
US |
Child |
08/094717 |
|
US |
Parent |
07/763805 |
|
US |
Child |
07/863198 |
|
US |